Finding GLP-1 Providers in Your City
To find a GLP-1 provider near you, start by deciding between an in-person clinic and a telehealth practice, then judge each on the same thing: does it run a real clinical intake, name a licensed prescriber, and offer follow-up. A search for weight loss near me will return endorphin ads, med spas, and physician practices side by side, and the format matters far less than whether an actual clinician is reviewing your history before anyone writes a prescription.
In-person or telehealth: which format fits?
Both can be legitimate, and both can be careless. An in-person clinic makes sense if you want lab draws, a physical exam, and a face across a desk, or if you already have conditions that need hands-on monitoring. Telehealth makes sense if the nearest obesity-focused practice is an hour away, if your schedule is unforgiving, or if you simply prefer video visits. Neither format guarantees good care.
The failure mode is the same in both directions. A weak in-person clinic hands out a script after a five-minute upsell; a weak telehealth service does the same through a web form. What separates the good ones is process. A provider working from the 2025 clinical practice guideline update on obesity pharmacotherapy will treat a GLP-1 as part of a plan, not a vending-machine transaction. That guideline is worth reading before you sit down with anyone, because it tells you what a serious conversation should sound like.
What should a good provider check first?
Before a GLP-1 is a reasonable choice, a prescriber needs a picture of you. That means body mass index and weight history, and it means asking whether obesity is already affecting how your body works. The recent Lancet work on the definition and diagnostic criteria of clinical obesity argues for exactly this: looking at function and related disease, not a single number on a chart.
Related conditions change the calculation. Prediabetes, high blood pressure, and metabolic dysfunction-associated steatotic liver disease all raise the stakes and can shift which treatment makes sense; the EASL-EASD-EASO guidelines on MASLD spell out how weight management ties into liver health. A careful clinician also asks about personal or family history of medullary thyroid cancer and pancreatitis, because those appear in the Wegovy prescribing information as reasons to avoid the drug. If nobody asks any of this, that tells you what kind of provider you have found.
How do the common options compare?
| Option | Best suited to | Main limitation |
|---|---|---|
| Hospital or academic obesity clinic | Complex cases, existing conditions | Waitlists, limited hours |
| Primary care physician | People who already have a trusted doctor | May lack obesity-specific focus |
| National telehealth brand | Convenience, flexible scheduling | Care can feel impersonal, variable follow-up |
| Local telehealth directory listing | People wanting a named nearby clinician | Quality varies by individual practice |
Where do the national names fit?
Several large services now dominate the online search results: Ro, Hims and Hers, Henry Meds, and manufacturer channels like LillyDirect and NovoCare. Some connect you to brand medication through insurance or manufacturer self-pay; others lean on compounded products. They differ in price, in how much follow-up they build in, and in whether you speak with the same clinician twice. None is automatically the right answer, and the convenience of a slick sign-up can mask thin clinical support.
If cost or access pushes you toward a cash-pay route, it helps to compare a national brand against a nearby practice that publishes its pricing and names its clinicians. A local physician-supervised medical weight-loss clinic is one such option, listed among the real field rather than standing in for it. The point is to see more than one door before you walk through one.
See also: Router Admin Access Guide
Is compounded medication a problem?
Many plans exclude weight-management drugs, so cash-pay and compounded semaglutide have become common. Here the distinction is real and worth stating plainly: compounded semaglutide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule as Wegovy, but it has not been through the approval process that produced the trial evidence behind the brand. That does not make it illegitimate, and for some people it is the only affordable route. It does mean the choice belongs with a prescriber who knows your case, not a checkout page.
What does the evidence say the medication actually does?
The trial record is strong and specific. STEP 3, published in 2021, paired semaglutide with intensive behavioral therapy and showed larger weight loss than behavioral therapy alone. STEP 8, published in 2022, compared weekly semaglutide against daily liraglutide and favored semaglutide. Those are separate trials with separate designs, not a single tournament, so read each on its own terms.
The harder lesson is what happens after. STEP 4 showed that continuing the drug maintained weight loss while stopping it led to regain, and the STEP 1 trial extension found that participants regained roughly two-thirds of their lost weight within a year of withdrawal. For guidance on how to structure long-term treatment around this, the AGA clinical practice guideline on pharmacological interventions for adults with obesity is a useful anchor. The practical takeaway: a provider who cannot describe what year two looks like has not thought the whole thing through.
Key takeaways
- Format matters less than process; judge in-person and telehealth on the same clinical standard.
- A serious provider checks BMI, weight history, related conditions, and thyroid and pancreatitis risk.
- Compounded semaglutide is not an FDA-approved product, even when the active molecule matches.
- Weight tends to return after stopping, so long-term follow-up is part of the choice, not an add-on.
Frequently asked questions
Should I look for an in-person clinic or a telehealth provider?
Either can be legitimate. In-person clinics suit people who want lab draws and a physical exam on site. Telehealth suits people who need flexible scheduling or live far from an obesity-focused practice. The quality of the prescriber matters more than the format.
What should a good GLP-1 provider check before prescribing?
Body mass index, weight history, related conditions such as prediabetes or fatty liver disease, current medications, and personal or family history of thyroid cancer or pancreatitis. A prescriber who asks none of this is a warning sign.
Are cash-pay GLP-1 programs a red flag?
Not by themselves. Many plans exclude weight-management drugs, so cash-pay is often the only route. The red flags are no clinical intake, no follow-up, and no named licensed clinician.
Is compounded semaglutide the same as Wegovy?
No. Compounded semaglutide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule, but it has not gone through the approval process behind the branded trial evidence.
What happens if I stop the medication?
Trial data show much of the lost weight tends to return after stopping. That makes ongoing follow-up and a long-term plan part of choosing a provider, not an afterthought.
